Massachusetts Financial Services Co. MA Sells 2,990 Shares of Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA)

Massachusetts Financial Services Co. MA reduced its position in Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSAFree Report) by 3.7% in the 3rd quarter, according to its most recent filing with the SEC. The firm owned 78,042 shares of the company’s stock after selling 2,990 shares during the period. Massachusetts Financial Services Co. MA owned 0.11% of Kiniksa Pharmaceuticals worth $1,356,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds also recently made changes to their positions in the company. Barclays PLC boosted its holdings in Kiniksa Pharmaceuticals by 7.9% in the third quarter. Barclays PLC now owns 175,525 shares of the company’s stock valued at $3,048,000 after acquiring an additional 12,867 shares during the last quarter. Victory Capital Management Inc. acquired a new stake in shares of Kiniksa Pharmaceuticals during the 3rd quarter worth approximately $176,000. Capula Management Ltd bought a new stake in shares of Kiniksa Pharmaceuticals during the third quarter worth approximately $892,000. Principal Financial Group Inc. acquired a new position in Kiniksa Pharmaceuticals in the third quarter valued at approximately $777,000. Finally, Hennion & Walsh Asset Management Inc. lifted its holdings in Kiniksa Pharmaceuticals by 89.5% in the third quarter. Hennion & Walsh Asset Management Inc. now owns 55,047 shares of the company’s stock valued at $956,000 after buying an additional 26,002 shares during the period. Institutional investors own 47.31% of the company’s stock.

Kiniksa Pharmaceuticals Stock Performance

Shares of NASDAQ:KNSA opened at $20.55 on Tuesday. The company has a 50 day moving average price of $18.39 and a two-hundred day moving average price of $17.27. The company has a market capitalization of $1.45 billion, a PE ratio of -186.80 and a beta of 0.24. Kiniksa Pharmaceuticals, Ltd. has a 52 week low of $10.29 and a 52 week high of $20.94.

Insider Buying and Selling

In other Kiniksa Pharmaceuticals news, CAO Michael R. Megna sold 9,316 shares of the business’s stock in a transaction dated Tuesday, December 19th. The stock was sold at an average price of $19.13, for a total value of $178,215.08. Following the completion of the transaction, the chief accounting officer now directly owns 17,005 shares of the company’s stock, valued at $325,305.65. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. In related news, insider John F. Paolini sold 28,600 shares of the stock in a transaction that occurred on Thursday, December 7th. The stock was sold at an average price of $17.65, for a total transaction of $504,790.00. Following the completion of the sale, the insider now directly owns 44,892 shares of the company’s stock, valued at approximately $792,343.80. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, CAO Michael R. Megna sold 9,316 shares of the firm’s stock in a transaction that occurred on Tuesday, December 19th. The stock was sold at an average price of $19.13, for a total transaction of $178,215.08. Following the sale, the chief accounting officer now owns 17,005 shares in the company, valued at $325,305.65. The disclosure for this sale can be found here. In the last quarter, insiders have sold 66,586 shares of company stock valued at $1,242,569. 54.23% of the stock is owned by company insiders.

Analysts Set New Price Targets

KNSA has been the subject of several recent research reports. Wedbush upped their target price on shares of Kiniksa Pharmaceuticals from $23.00 to $25.00 and gave the company an “outperform” rating in a research report on Tuesday, January 2nd. TheStreet downgraded Kiniksa Pharmaceuticals from a “c” rating to a “d+” rating in a report on Friday, November 3rd.

View Our Latest Analysis on Kiniksa Pharmaceuticals

Kiniksa Pharmaceuticals Profile

(Free Report)

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that completed Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response.

See Also

Want to see what other hedge funds are holding KNSA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSAFree Report).

Institutional Ownership by Quarter for Kiniksa Pharmaceuticals (NASDAQ:KNSA)

Receive News & Ratings for Kiniksa Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kiniksa Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.